The distinction between pulmonary large cell neuroendocrine carcinoma and small cell carcinoma is difficult in some cases. Some propose that these carcinomas should be classified as one high-grade neuroendocrine carcinoma. We examined biological features of small cell carcinoma (n ¼ 23), large cell neuroendocrine carcinoma (n ¼ 17), and classic large cell carcinoma (n ¼ 12). The average ratio of nuclear diameter of the tumor cells to that of lymphocytes for small cell carcinoma was smaller than that for large cell neuroendocrine carcinoma (Po0.0001). The frequencies of the expressions of CD56, mASH1, TTF-1, and p16 were higher and that of NeuroD was lower in small cell carcinoma than in large cell neuroendocrine carcinoma. The frequency of loss of heterozygosity at 3p was higher in high-grade neuroendocrine carcinomas than in classic large cell carcinoma (P ¼ 0.0002). Allelic losses at D5S422 (5q33) were more frequent in small cell carcinoma than in large cell neuroendocrine carcinoma (P ¼ 0.0091). Mean fractional regional loss indices of the tumors were 0.38, 0.65, and 0.72 for patients with classic large cell carcinoma, large cell neuroendocrine carcinoma, and small cell carcinoma, respectively (P ¼ 0.0003). Five-year overall survivals of patients with classic large cell carcinoma, large cell neuroendocrine carcinoma and small cell carcinoma in stage I were 67, 73, 60%, respectively. Patients with NeuroD expression had better survivals, and those with p63 expression had poorer survivals in large cell neuroendocrine carcinoma. Patients with TTF-1 expression had poorer survivals in small cell carcinoma. Our data suggest that large cell neuroendocrine carcinoma and small cell carcinoma are different morphologically, phenotypically, and genetically, although there are some overlapping features. Although further studies are needed to analyze the biological behavior of high-grade neuroendocrine carcinomas including sensitivity to chemotherapy, the pathological distinction of large cell neuroendocrine carcinoma from small cell carcinoma may be necessary to treat the patients with neuroendocrine tumors.
all tumors with pure histology were called small cell carcinomas. 3 Tumor cells of small cell carcinoma are round, oval, or spindle-shaped; usually less than the size of three small resting lymphocytes, and have scant cytoplasm, finely granular chromatin, and absent or inconspicuous nucleoli. 3 The tumor cells of large cell neuroendocrine carcinoma are generally large and polygonal with moderate to abundant cytoplasm; nuclear chromatin is coarsely granular and nucleoli are prominent. 3, 4 Distinguishing large cell neuroendocrine carcinoma from small cell carcinoma can be difficult in some cases, however. In a study by Travis et al, 5 there was unanimous diagnostic agreement on 70% of small cell carcinomas and 40% of large cell neuroendocrine carcinomas in surgically resected neuroendocrine tumors of the lung that were reviewed independently by five pulmonary pathologists. Most of the disagreements concerned the distinction between small cell carcinoma and large cell neuroendocrine carcinoma. Marchevsky et al 6 reported that small cell carcinoma and large cell neuroendocrine carcinoma had a continuum of cell size. They and others suggested that the tumors should be combined into a single group in daily practice as a high-grade neuroendocrine carcinoma. [6] [7] [8] Small cell carcinomas respond initially to chemotherapy, but they frequently relapse and metastasize; whereas surgery is advocated for the treatment of patients with large cell neuroendocrine carcinoma, but survival rates are poor. However, it has been reported that patients with stage I large cell neuroendocrine carcinoma, who were treated with either neoadjuvant or postoperative adjuvant chemotherapy, had significantly higher survival rates than patients treated only with surgery. 9 The aim of this study was to elucidate the morphological, phenotypical, and genetic characteristics of large cell neuroendocrine carcinoma and compare them with those of small cell carcinoma, to determine the biological differences of these two tumors, and to evaluate the utility of these markers for the diagnosis of neureondocrine tumors and the prognosis according to the expression of these proteins.
Materials and methods

Tumor Specimens
We reviewed the histologic features of large cell neuroendocrine carcinoma reported in our recent paper 10 and the cases diagnosed after the publication of the manuscript. Tumors were classified according to the WHO classification system for lung carcinoma. 3, 11 We analyzed 17 cases of large cell neuroendocrine carcinoma in stage I (T1N0M0 or T2N0M0): a tumor that does not invade the adjacent organs (T1 or T2), has no regional lymph node metastasis (N0), and no distant metastasis (M0). One case of large cell neuroendocrine carcinoma was combined with squamous cell carcinoma. We also analyzed 12 cases of classic large cell carcinoma in stage I, nine cases of carcinoid tumors (seven typical carcinoids and two atypical carcinoids) in stage I, and 23 cases of small cell carcinoma with limited disease (17 cases in stage I and six cases in stages II-IV). Three small cell carcinomas were combined with squamous cell carcinoma, and one was combined with large cell neuroendocrine carcinoma. All tumors, except one large cell neuroendocrine carcinoma, were resected surgically at Chiba University Hospital between 1987 and 2005. The one large cell neuroendocrine carcinoma was resected at Narita Red Cross Hospital in 2004. The tumors in all cases were resected completely. We performed immunohistochemical staining for all large cell neuroendocrine carcinomas, small cell carcinomas, classic large cell carcinomas, and carcinoid tumors studied. Neuroendocrine differentiation was detected for large cell neuroendocrine carcinoma by positive immunohistochemical staining for chromogranin A, synaptophysin, or CD56. We confirmed lack of neuroendocrine differentiation in all classic large cell carcinomas. Two experienced pulmonary pathologists (KH and YN) classified the tumors independently. Discordant independent readings were resolved by simultaneous review performed by the two readers. Informed consent was obtained from all patients.
One of 12 patients with classic large cell carcinoma, and seven of 23 with small cell carcinoma underwent preoperative chemotherapy. One patient with classic large cell carcinoma, five with large cell neuroendocrine carcinoma, and 13 with small cell carcinoma underwent postoperative adjuvant chemotherapy, and one patient with large cell neuroendocrine carcinoma and two with small cell carcinoma underwent postoperative radiotherapy.
Morphometric Study
The nuclear diameter was measured in each case of large cell neuroendocrine carcinoma and small cell carcinoma with a CAS 200 cellular imaging system using a Â 40 objective lens (Becton Dickinson and Company, San Jose, CA, USA). The accuracy of the image measurement was confirmed with the standard objective micrometer (Nikon, Tokyo, Japan). The nuclear diameters of 100 tumor cells and the nuclear diameters of 20 mature lymphocytes were measured for each specimen. The measurements were made by one of the authors (KH). The mean and standard deviation were then calculated.
Immunohistochemistry
All tumors were examined by immunohistochemical staining. Sections (4 mm) were cut from formalin-fixed paraffin-embedded tissues and placed on silanized slides (DakoCytomation, Glostrup, Denmark). They were stained with polyclonal anti-chromogranin A antibody (prediluted; Nichirei, Tokyo, Japan), polyclonal anti-synaptophysin antibody (prediluted; DakoCytomation), polyclonal anti-Neuro D antibody (1: We used a Histofine Simple Stain Kit (Nichirei, Tokyo, Japan) for immunostaining. To improve the staining pattern, the tissues were pretreated with microwaves for 15 min in citrate buffer (10 mM pH 6.0) before staining with anti-CD56 antibody, anti-CK34bE12 antibody, anti-Neuro D antibody, and anti-p16 antibody; or were heated in an autoclave at 1211C for 15 min before staining with anti-synaptophysin antibody, anti-PTEN antibody, anti-TTF-1 antibody, and anti-mASH1 antibody. The tissues were heated in an autoclave at 1211C for 15 min in DAKO Target Retrieval Solution (S1700) (DakoCytomation) before staining with anti-p63 protein antibody. Reactivity was considered negative if less than 10% of tumor cells stained.
Microdissection and DNA Extraction
DNA was extracted from paraffin-embedded materials as described previously. 10 Polymorphic DNA Markers and Polymerase Chain Reaction-Loss of Heterozygosity
We examined previously the same cohort for the loss of heterozygosity (LOH) at 13 microsatellite markers: D3S1234(3p14.2), D3S1481(3p14.2), D3S1295(3p21.1), D3S1581(3p21.3), D5S407(5q11), D5S410(5q31.3), D5S422(5q33), D9S171(9p21), IFNA(9p21), D10S249 (10p15.3), D10S1686(10q22.3), D13S153(13q14), and ALE3/P53ivs1b(TP53). LOH was defined as a reduction of an allele's peak height by at least 50% in the tumor, compared with the normal sample. 10 
Calculation of Fractional Regional Loss Index
The fractional regional loss index was calculated as follows:
Fractional regional loss ¼ (total number of chromosomal regions with LOH)/(total number of informative regions).
Methylation Analysis
We examined previously the same cohort for the methylation state of the p16 gene by methylationspecific polymerase chain reaction (PCR).
10,14
Survival Analysis
Because all cases with classic large cell carcinoma, large cell neuroendocrine carcinoma, and carcinoid tumors and seven of 23 cases with small cell carcinoma were in stage I, survival of these cases was determined.
The interval between the date of surgery and the date of the first local and distant recurrence was defined as disease-free survival, and the time after surgery until death was defined as the overall survival. Kaplan-Meier curves and survival estimates were calculated, 15 and the Brestow-GehanWilcoxon test was used to test for differences between groups.
Statistical Analysis
All statistical calculations were made with the StatView software package (SAS Institute Inc., Cary, NC, USA). Differences of the ratio of the nuclear diameter of the tumor cells to that of the lymphocytes between large cell neuroendocrine carcinoma and small cell carcinoma were analyzed by Student's t-test. A w 2 test was used to evaluate the immunohistochemical and methylation analysis for the lung cancer subtypes and the differences of the frequency of LOH at specific regions among lung cancer subtypes. Differences in fractional regional loss indices among three lung cancer subtypes were tested by the Kruskal-Wallis test, and those between large cell neuroendocrine carcinoma and small cell carcinoma were tested by Mann-Whitney U-test. Probability values of Po0.05 were regarded as statistically significant.
Results
Microscopic Study
Examples of histological preparations of small cell carcinoma and large cell neuroendocrine carcinoma are presented in Figure 1a and b. The tumor cells of large cell neuroendocrine carcinoma are polygonal with a low nuclear to cytoplasmic (N/C) ratio; are larger than small cell carcinoma cells; have In two cases with combined small cell carcinoma and squamous cell carcinoma, the predominant histological type was squamous cell carcinoma, in one case, the predominant histological type was small cell carcinoma. In a case with combined small cell carcinoma and large cell neuroendocrine carcinoma, the predominant histological type was large cell neuroendocrine carcinoma, and in a case with combined large cell neuroendocrine carcinoma and squamous cell carcinoma, the predominant histological type was large cell neuroendocrine carcinoma.
Morphometric Study
The frequency distribution of tumor nuclear diameter/lymphocyte size ratios is shown in a histogram (Figure 2a and b). The peak of tumor nuclear diameter/lymphocyte size ratios was between 3 and 4 for large cell neuroendocrine carcinoma and between 2 and 3 for small cell carcinoma. The average tumor nuclear diameter/lymphocyte size ratios were 3.2270.86 for large cell neuroendocrine carcinoma and 2.7570.86 for small cell carcinoma. The differences between tumor nuclear diameter/ lymphocyte size ratios of large cell neuroendocrine carcinoma and small cell carcinoma were significant (Po0.0001) according to the Student's t-test.
Immunohistochemistry
Immunohistochemical study showed that 59% of large cell neuroendocrine carcinoma and 36% of small cell carcinoma stained with antibody for chromogranin A (P ¼ 0.1630). Seventy seven percent of large cell neuroendocrine carcinoma and 57% of small cell carcinoma stained with antibody for synaptophysin (P ¼ 0.1910). Fifty three percent of large cell neuroendocrine carcinoma and 96% of small cell carcinoma stained with antibody for CD56 Large cell neuroendocrine carcinoma K Hiroshima et al (P ¼ 0.0018) ( Table 1) . Fifteen of 17 pure large cell neuroendocrine carcinomas and 19 of 23 small cell carcinomas were completely CK34bE12 negative. However, tumor cells of two of pure large cell neuroendocrine carcinomas and four of small cell carcinomas were stained focally with antiCK34bE12. In large cell neuroendocrine carcinomas and small cell carcinomas combined with squamous cell carcinoma, the last component showed marked immunoreactivity with CK34bE12.
The cytoplasm of bronchial gland cells was stained positively for mASH1 in normal lung tissue, and no cells of the bronchial epithelium were stained; both cytoplasm and nucleus of the tumor cells were stained. A few cells in normal bronchial epithelium had cytoplasmic granules that stained positively for NeuroD; both cytoplasm and nucleus of tumor cells were stained with that antibody. Type II alveolar epithelial cells in normal lung tissue were stained with the antibody for TTF-1; only nuclei of tumor cells were stained. Nuclei of basal cells of bronchial epithelium were stained with anti-p63 antibody, and only nuclei of tumor cells were stained. Tumor cells were stained focally with anti-p63 antibody in four small cell carcinomas, and one carcinoid tumor. Because we defined negative reactivity as fewer than 10% of tumor cells stained, these cases were negative for p63. This pattern contrasted with tumor cells that were stained uniformly in classic large cell carcinoma and large cell neuroendocrine carcinoma. Only cells with nuclear activity for anti-p16 antibody were recorded. Prostatic hyperplasia tissue was used for the positive control for PTEN; both cytoplasm and nucleus of the tumor cell stained with the antibody. Table 2 lists the total number and percentage of positive cases in each histological category for each antibody. For cases with combined small cell carcinoma with non-small-cell carcinoma, immunohistochemical staining of the small cell carcinoma is described in Table 2 , and for a case with combined large cell neuroendocrine carcinoma, that for the large cell neuroendocrine carcinoma is described. The differences of the frequency of the expressions of mASH1, NeuroD, TTF-1, p63, p16, and PTEN were statistically significant among classic large cell carcinoma, large cell neuroendocrine carcinoma, small cell carcinoma, and carcinoid tumors. The differences of staining between high-grade neuroendocrine carcinoma were analyzed. The Large cell neuroendocrine carcinoma K Hiroshima et al frequencies of the expressions of mASH1, TTF-1, and p16 were higher in small cell carcinoma than in large cell neuroendocrine carcinoma, and those of the expressions of NeuroD, p63, and PTEN were higher in large cell neuroendocrine carcinoma than in small cell carcinoma. The differences of the frequency of the expressions of mASH1, NeuroD, TTF-1, and p16 were statistically significant between high-grade neuroendocrine carcinoma. The results of immunohistochemical staining for combined neuroendocrine carcinomas according to each component are shown in Table 3 . mASH1 was expressed only in the component of small cell carcinoma in all cases of combined small cell carcinoma and squamous cell carcinoma. TTF-1 was expressed only in the component of small cell carcinoma in all cases of combined small cell carcinoma and squamous cell carcinoma and in both components in one case of combined small cell carcinoma and large cell neuroendocrine carcinoma.
Polymorphic DNA Markers and PCR-LOH
Four specific 3p regions (D3S1234, D3S1481, D3S1295, and D3S1581), three specific 5q regions (D5S407, D5S410, and D5S422), two specific 9p regions (D9S171 and IFNA), one specific 10p region (D10S249), one specific 10q region (D10S1686), one specific 13q region (D13S153), and one specific 17p region (ALE3/P53ivs1b) were analyzed. The frequencies of LOH in specific regions are shown in Figure 3 . The frequency of LOH at 10q is not shown because the number of informative cases at 10q was small. The frequency of LOH at 3p was higher in high-grade neuroendocrine carcinoma than in classic large cell carcinoma and the difference was statistically significant (P ¼ 0.0002). The frequency of LOH at 13q was also higher in high-grade neuroendocrine carcinoma than in classic large cell carcinoma, but the difference was not statistically significant. The frequency of LOH at 5q, 17p, and 10p was higher in small cell carcinoma than in large cell neuroendocrine carcinoma and classic large cell carcinoma, and the frequency of LOH at 9p was higher in large cell neuroendocrine carcinoma and classic large cell carcinoma than in small cell carcinoma, but the differences were not significant. Allelic losses at D5S422 were observed in nine of 11 cases of small cell carcinoma (82%) and in one of six cases of large cell neuroendocrine carcinoma (17%). 
Large cell neuroendocrine carcinoma K Hiroshima et al
The difference in frequency between small cell carcinoma and large cell neuroendocrine carcinoma was statistically significant (P ¼ 0.0091). Allelic losses at ALE3/P53ivs1b were observed in of all of seven cases of small cell carcinoma (100%) and in eight of 12 cases of large cell neuroendocrine carcinoma (67%). However, the difference in frequency between small cell carcinoma and large cell neuroendocrine carcinoma was not statistically significant (P ¼ 0.0856). Mean fractional regional loss indices of the tumors were 0.38, 0.65, and 0.72 for patients with classic large cell carcinoma, large cell neuroendocrine carcinoma, and small cell carcinoma, respectively. The differences of fractional regional loss indices among the three types of the tumor were significant (P ¼ 0.0003); however, those between high-grade neuroendocrine carcinomas were not (P ¼ 0.1123). Mean 3p fractional regional loss indices of the tumor were 0.20, 0.76, and 0.79 for patients with classic large cell carcinoma, large cell neuroendocrine carcinoma, and small cell carcinoma, respectively. The differences of fractional regional loss indices among the three types of tumor were significant (P ¼ 0.0004); however, those between high-grade neuroendocrine carcinomas were not (P ¼ 0.5689).
Methylation Analysis
Hypermethylation of the p16 gene was observed in four of 12 informative cases of classic large cell carcinoma (33%), three of 10 informative cases of large cell neuroendocrine carcinoma (30%), and three of 14 informative cases of small cell carcinoma (21%). The difference of the frequency was not significant (P ¼ 0.7825).
Survival Analysis
Five-year overall survivals of patients with classic large cell carcinoma, large cell neuroendocrine carcinoma, small cell carcinoma, and carcinoid tumors were 64, 73, 60, and 89%, respectively. The differences of overall survival among the five subtypes were not significant. Five-year disease-free survivals of patients with classic large cell carcinoma, large cell neuroendocrine carcinoma, small cell carcinoma, and carcinoid tumors were 64, 58, 62, and 89%, respectively. The differences of disease-free survival among the five subtypes were not significant.
We examined the correlations between survival of patients with high-grade neuroendocrine carcinoma and the expressions of the proteins examined in this study. Comparing patients with/without a specific protein expression, patients with NeuroD expression had better 5-year disease-free (80/46%, P ¼ 0.0336) and overall (91/50%, P ¼ 0.0355) survivals. Patients with mASH1 expression had poorer 5-year disease-free (46/80%, P ¼ 0.2016) and overall (60/80%, P ¼ 0.4395) survivals, but the difference was not significant. Patients with p63 expression had poorer 5-year disease-free (33/61%, P ¼ 0.0583) and overall (33/71%, P ¼ 0.0428) survivals. Patients with TTF-1 expression had poorer 5-year diseasefree (23/69%, P ¼ 0.0419) and overall (19/81%, P ¼ 0.0117) survivals. Other biomarkers did not have prognostic significance for either disease-free or overall survivals in high-grade neuroendocrine carcinoma.
We examined subset analysis of the correlations between survival of patients with high-grade neuroendocrine carcinoma and the expressions of the proteins. Patients with NeuroD expression had better 5-year disease-free (74/33%, P ¼ 0.0413) and overall (89/50%, P ¼ 0.0887) survivals in large cell neuroendocrine carcinoma. Patients with mASH1 expression had poorer 5-year overall survival (48/ 100%) in small cell carcinoma, but the difference was not significant. Patients with p63 expression had poorer 5-year disease-free (33/64%, P ¼ 0.0394) and overall (33/83%, P ¼ 0.0157) survivals (Figure 4a ) in large cell neuroendocrine carcinoma. Patients with TTF-1 expression had poorer 5-year disease-free (0/77%, P ¼ 0.0269) and overall (0/77%, P ¼ 0.0208) survivals in small cell carcinoma (Figure 4b ). 
Discussion
Achaete-scute homolog 1 (termed mASH1 in rodents, hASH1 in humans) is a basic helix-loophelix (bHLH) transcription factor that is important in the early development of neural and neuroendocrine progenitor cells in many tissues. 16 The NeuroD gene is a bHLH gene and regulates neurogenesis, and it is reported that it maps to chromosome 2q32. 17 NeuroD is expressed transiently in developing neurons in the central and peripheral nervous systems but is not expressed in nearby neuronal progenitors that are still undergoing cell division.
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mASH1 is required at an early stage in neuronal differentiation and initiates a differentiation program involving NeuroD. 19 It is reported that hASH1 is expressed selectively in normal fetal pulmonary neuroendocrine cells 20 as well as in pulmonary large cell neuroendocrine carcinoma (56.7%) and small cell carcinoma (71.8%). 21 The frequency of expression of mASH1 in our study was 59% in large cell neuroendocrine carcinoma and 87% in small cell carcinoma. The frequencies of expression of mASH1 in large cell neuroendocrine carcinoma and small cell carcinoma are comparable to those reported in a previous paper. 21 It was reported that the expression of NeuroD was detected in 24.3% of gastric adenocarcinomas, but not in gastric neuroendocrine carcinomas, including small cell carcinomas. 22 The expression of NeuroD in our study was 59% in large cell neuroendocrine carcinoma and 13% in small cell carcinoma. The frequency of the expression of NeuroD was higher in large cell neuroendocrine carcinoma, but it was also observed in carcinoid tumor and classic large cell carcinoma. NeuroD may be related to neuroendocrine differentiation in nonsmall-cell carcinoma including large cell neuroendocrine carcinoma. It was reported that hASH1 expression was associated with a poorer prognosis in small cell carcinoma patients. 21 In our study, the relation between the survival of patients and the expression of mASH1 was not significant; however, NeuroD expression was associated with good prognosis in large cell neuroendocrine carcinoma.
A putative tumor suppressor gene, PTEN, was identified at 10q23 and is thought to play an important role in the control of cell proliferation, apoptosis, differentiation, 23, 24 and break cell cycle progression by inhibiting the phosphatidylinositol 3 0 -kinase pathway. 25, 26 PTEN was mutated or deleted homozygously in glioma, endometrial, and breast carcinoma tumors. [27] [28] [29] It was reported that PTEN mutations were identified in small cell carcinomas, but not in non-small-cell carcinomas. 30, 31 We found that the frequency of the loss of expression of PTEN was higher in high-grade neuroendocrine carcinoma than in classic large cell carcinoma or carcinoid tumor, and the differences were significant; however, the difference was not significant between large cell neuroendocrine carcinoma and small cell carcinoma.
TTF-1 is a tissue-specific transcription factor that mediates cell determination and differentiation in thyroid, lung, and brain. It is expressed in thyroid follicular cells, human fetal lung, and alveolar type II epithelial cells after birth. TTF-1 was detectable in pulmonary adenocarcinomas, 32, 33 small cell carcinomas, large cell neuroendocrine carcinomas, carcinoid tumors, and classic large cell carcinomas but not in pulmonary squamous cell carcinomas. 33, 34 The prognostic value of TTF-1 was evaluated in non-small-cell carcinomas, and contradictory results were reported. 35, 36 We found that TTF-1 was detectable in 33% of classic large cell carcinoma cases, 24% of large cell neuroendocrine carcinoma, and 57% in small cell carcinoma. TTF-1 had a poor prognostic implication in small cell carcinoma in our study.
p63 is a p53 homologue mapped to chromosome 3q27-28. p63 plays a role in stem cell commitment in squamous epithelium. 37 Some reported that p63 was expressed in pulmonary squamous cell carcinoma but not in small cell carcinomas, 37, 38 whereas others reported that large cell neuroendocrine carcinoma and small cell carcinoma had p63 expression. 39, 40 The reported differences of frequency of p63 expression in small cell carcinoma may be due to different identification methods for positive cells. Zhang et al 38 reported that they defined the tumor as p63-negative if less than 10% of tumor cells were stained. Pelosi et al 39 reported that they defined the tumor as p63-positive if nuclear staining of the tumor cells was observed. It is reported that p63 staining cases have a better outcome in patients with squamous cell carcinoma 41, 42 but a poor outcome in patients with neuroendocrine tumors. 40 In our study, half of classic large cell carcinoma and 18% of large cell neuroendocrine carcinoma cases stained with antip63 antibody, but 4% of small cell carcinoma cases was p63-positive. Patients with p63 expression had poorer 5-year overall survival (33%) than those without its expression (83%) in large cell neuroendocrine carcinoma (P ¼ 0.0157).
Recently, a genome-wide high-resolution search for LOH was made of small cell carcinoma and nonsmall-cell carcinoma cell lines. 43, 44 These studies found that some LOH was common in both small cell carcinoma and non-small-cell carcinoma subtypes, whereas loss was subtype-specific in others. It has been suggested that the genetic alterations undergone by small cell carcinoma and non-smallcell carcinoma are different. There are contradictory reports about the differences of genetic changes between small cell carcinoma and large cell neuroendocrine carcinoma. For example, LOH at 3p, 5q, 11q, 13q, 17p and mutations in the p53 and ras genes were present both in small cell carcinomas and large cell neuroendocrine carcinomas. 45 c-myc amplification was observed with a similar frequency in small cell carcinoma (20%) and large cell neuroendocrine carcinoma (23%). 46 Small cell Large cell neuroendocrine carcinoma K Hiroshima et al carcinoma and large cell neuroendocrine carcinoma were indistinguishable by gene expression profiles, and high-grade neuroendocrine carcinoma of the lung can be classified into two groups independent of small cell carcinoma and large cell neuroendocrine carcinoma. 8 However, although both small cell carcinoma and large cell neuroendocrine carcinoma shared several chromosomal aberrations including losses of 3p, 4q, 5q, and 13q and gains of 5p, a gain of 3q and a loss of 10q, 16q, and 17p were observed frequently in small cell carcinoma but not in large cell neuroendocrine carcinoma, and a gain of 6p occurred more frequently in large cell neuroendocrine carcinoma. 47 Our study found that the frequency of LOH at 3p and 13q was high in large cell neuroendocrine carcinoma and small cell carcinoma, it was higher at 5q and 17p in small cell carcinoma than in large cell neuroendocrine carcinoma, and it was higher at 9p in large cell neuroendocrine carcinoma than in small cell carcinoma. Allelic losses at D5S422 were more frequent in small cell carcinoma than in large cell neuroendocrine carcinoma (P ¼ 0.0091). We conclude that there are different genetic changes in small cell carcinoma and large cell neuroendocrine carcinoma and also common abnormalities between these two subtypes.
Chromogranin A and synaptophysin are the most reliable immunohistochemical markers to detect neuroendocrine differentiation in neuroendocrine lung tumors.
3,4,48 CD56 or neural cell adhesion molecule is also a sensitive and specific marker in confirmation of neuroendocrine differentiation in malignant neoplasms. 48, 49 It is reported that CD56 is useful for the immunohistochemical differentiation of small cell carcinoma and large cell neuroendocrine carcinoma from nonneuroendocrine carcionomas. [49] [50] [51] The frequencies of the expressions of CD56 were higher in small cell carcinoma (96%) than in large cell neuroendocrine carcinoma (53%), and the difference was statistically significant in our study.
Large cell neuroendocrine carcinoma is defined as a large cell carcinoma showing histological features such as organoid nesting, trabecular, rosette-like and palisading patterns; and neuroendocrine differentiation confirmed by immunohistochemistry or electron microscopy. 3, 11 The tumor cells are polygonal with a low N/C ratio; are larger than small cell carcinoma cells; have moderate to abundant eosinophilic cytoplasm; have a high mitotic rate (11 or more mitotic figures per 10 high-power fields), prominent nucleoli, and coarsely granular nuclear chromatin. A large infarct-like zone of necrosis is present in large cell neuroendocrine carcinoma. Small cell carcinoma is composed of small (less than the size of three small resting lymphocytes), round to fusiform cells with a high N/C ratio. 3, 11 The cells have a high mitotic rate, absent or inconspicuous nucleoli, and finely granular nuclear chromatin.
It is reported that there exist borderline cases between large cell neuroendocrine carcinoma and small cell carcinoma in high-grade neuroendocrine carcinoma. 52 Difficulty of diagnosis in high-grade neuroendocrine carcinoma is thought to occur as a result of variety of reasons, including the continuum of cell size and morphology between small cell carcinoma and large cell neuroendocrine carcinoma, and poor sampling and tissue artifacts. 53 We propose that one of the main reasons why there are differences between observers in histological diagnosis of high-grade neuroendocrine carcinoma may be the presence of tumors shown in Figure 1c in this study. We diagnose this tumor as small cell carcinoma because the N/C ratio is high and the cytoplasm is not abundant. However, some pathologists may diagnose the same specimen as large cell neuroendocrine carcinoma because the shape of the tumor cell is polygonal, the nuclear diameter is larger than that of typical small cell carcinoma, and nucleoli are usually observed. The average tumor nuclear diameter/lymphocyte size ratios in tumors shown in Figure 1c is 2.91, and significantly larger than that in typical small cell carcinoma (2.62). Tumors as shown in Figure 1c have a unique immunohistochemical phenotype, such that all tumors are CD56 positive, chromogranin A negative, and synaptophysin negative (n ¼ 10). Methylation of p16 gene is observed in half of the tumors shown in Figure 1c , but not observed in typical small cell carcinoma. However, the smaller nuclear size, the expression of CD56, mASH1, and p16, and the LOH analysis have supported the recognition that tumors as shown in Figure 1c are small cell carcinoma.
In the present study, the 5-year overall survivals of patients with classic large cell carcinoma, large cell neuroendocrine carcinoma, small cell carcinoma, and carcinoid tumors were 64, 73, 60, and 89%, respectively. The differences of overall survival among the four subtypes were not significant. Fiveyear survival for small cell carcinoma in this study was good, because we evaluated the survival of small cell carcinoma in stage I. These cases were operated in early stage and underwent preoperative and/or postoperative chemotherapy. We had previously analyzed small cell carcinoma resected surgically at our institute and reported that the 5-year overall survival for patients with small cell carcinoma in all stages was 16.4%. 54 In summary, we found that antibodies to CD56, mASH1, NeuroD, TTF-1, and p16 made up a useful panel of immunohistochemical markers for the differential diagnosis of large cell neuroendocrine carcinoma and small cell carcinoma, and that NeuroD expression correlated with a good survival and p63 with a poor survival in patients with large cell neuroendocrine carcinoma, and TTF-1 with a poor survival in patients with small cell carcinoma. Additional studies in larger series are needed to analyze the biological behavior of large cell neuroendocrine carcinoma and small cell carcinoma including sensitivity to chemotherapeutic agents.
